(Updates with closing share price in sixth paragraph.)
Aug. 5 (Bloomberg) -- CVS Caremark Corp., the biggest provider of prescription drugs in the U.S., reported profit that beat analysts’ estimates after adding new customers in its pharmacy services business.
Second-quarter net income rose 11 percent to $1.25 billion, or $1.06 a share, from $1.12 billion, or 91 cents, a year earlier, the Woonsocket, Rhode Island-based company said today in a statement. Excluding one-time items, earnings were $1.13 a share, 3 cents above the average of 21 estimates compiled by Bloomberg.
CVS operates retail pharmacies as well as a unit managing patients’ prescription drug benefits. Pharmacy benefit managers have been facing increasing drug prices from expensive new treatments, even as they add more customers from an expansion of insurance under the Patient Protection and Affordable Care Act, also known as Obamacare.
CVS’s total revenue rose 11 percent to $34.6 billion, with a 16 percent gain in the pharmacy benefit management unit and a 4.5 percent rise by retail stores. Same-store sales rose 3.3 percent, despite the company no longer selling cigarettes in its retail locations.
The company said it was raising its adjusted earnings per share forecast for the year, to $4.43 to $4.51 per share, from $4.36 to $4.50 per share.
CVS fell less than 1 percent to $77.22 at 4 p.m. New York time. The shares have gained 25 percent in the last 12 months.